Last reviewed · How we verify
Timolol + LCP
Timolol is a non-selective beta-adrenergic receptor blocker, and LCP is a beta-blocker.
Timolol is a non-selective beta-adrenergic receptor blocker, and LCP is a beta-blocker. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | Timolol + LCP |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Drug class | Beta-blocker |
| Target | Beta-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Timolol works by blocking the effects of the hormone epinephrine, also known as adrenaline, and LCP has a similar mechanism of action. This leads to a decrease in heart rate and blood pressure, which can help to reduce the workload on the heart and prevent angina attacks.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Bradycardia
- Dyspnea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Timolol + LCP CI brief — competitive landscape report
- Timolol + LCP updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Nice portfolio CI